Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Membranous nephropathy (MN), a leading cause of nephrotic syndrome in adults, has shown an increasing incidence in recent years. Although international treatment guidelines for MN has been well established, evidence of its management in patients with concomitant tumors remains limited. Standard MN treatment regimens typically rely on glucocorticoids, immunosuppressants and biologics, which may compromise the body's anti-tumor immunity. This therapeutic conflict between "anti-tumor immunity" and "immunosuppression" complicates drug selection particularly challenging for MN patients with tumors, and a safe and effective consensus regimen remains currently lacking. This study aims to investigate the efficacy and safety of tacrolimus combined with Tripterygium wilfordii (TwHF) in MN patients with concomitant tumors, evaluating whether this regimen can effectively reduce proteinuria and alleviate renal injury without increasing the risk of tumor progression.
A retrospective analysis was conducted on the clinical data of 7 MN patients with tumors in a stable phase who were treated with tacrolimus combined with TwHF between January 2020 and August 2025. Primary outcomes included the clinical remission rate, time to achieve clinical remission, time to achieve complete remission (CR), and tumor recurrence during follow-up. Secondary outcomes included changes in 24-hour urine protein quantification, serum albumin, serum creatinine, and the occurrence of treatment-related adverse events.
The study included 7 patients (5 males, 2 females) with a mean age of 64.29 ± 4.85 years. Baseline median 24-hour urine protein was 6.55g (IQR 3.14 - 9.07), serum albumin was 30.24 ± 9.36 g/L, and serum creatinine was 77.14 ± 24.10 μmol/L. During a median follow-up of 30 months, all 7 patients (100%) achieved either complete or partial remission, including 6 patients (85.7%) with CR and 1 patient (14.3%) with partial remission. The median time to achieve remission for all 7 patients was 3 months (IQR 1.0 - 3.0), and the median time to achieve CR for the 6 CR patients was 15 months (IQR 11.3 - 18.8). The 24-hour urine protein quantification significantly decreased from a baseline median of 6.55g (IQR 3.14 - 9.07) to 1.61g (IQR 0.70 - 2.24) at 6 months (p < 0.05) and further to 0.23g (IQR 0.11 - 0.29) at 15 months (p < 0.05)(Fig.1). Serum albumin levels significantly increased from a baseline of 30.24 ± 9.36 g/L to 35.7 ± 6.89 g/L at 6 months (p < 0.05) and to 38.64 ± 6.02 g/L at 15 months (p < 0.05)(Fig.2). Serum creatinine levels remained stable (p > 0.05)(Fig.3). During the treatment period, one patient experienced a respiratory tract infection. Following infection, the treatment with tacrolimus and TwHF was temporarily suspended, and antibiotics were administered. The patient recovered and subsequently resumed the previous treatment. No tumor recurrence was observed, and no other serious adverse events occurred.
Our findings provide evidence that the combination of tacrolimus and TwHF is an effective and well-tolerated therapeutic option for the treatment of membranous nephropathy with concomitant tumors.
